Manufacturer record
Primus Pharmaceuticals: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
8 batches manufactured by Primus Pharmaceuticals (Himachal Pradesh) were declared Not of Standard Quality between May 2021 and February 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: PD052505A, Amoxycillin & Potassium Clavulanate Injection IP 1.2 gm (exp Apr 2027). CDTL, Hyderabad (CDSCO lab) found it not of standard quality: The sample received does not conform to I.P. 2022 specification with respect to the Assay for the content of potassium clavulanate. Listed in the February 2026 alert.
Records by type
8 records linked to Primus Pharmaceuticals in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Amoxycillin & Potassium Clavulanate Injection IP 1.2 gm | Batch PD052505AMfg May 2025 · Exp Apr 2027 | The sample received does not conform to I.P. 2022 specification with respect to the Assay for the content of potassium clavulanate equivalent to clavulanic acid only.Assay | CDTL, HyderabadCDSCO lab | Feb 2026 |
| Pregabalin & Nortriptyline Tablets | Batch PT-042515Mfg Apr 2025 · Exp Mar 2027 | The sample does not conform to the claim with respect to Assay in Nortriptyline.Assay | DTL JaipurState lab | Jan 2026 |
| Ibuprofen Suspension 100mg/5ml | Batch PL-022502Mfg Feb 2025 · Exp Jan 2027 | Test for pHpH | DTL, Bengaluru, KarnatakaState lab | Jan 2026 |
| Hyoscine Butylbromide Tablets IP (BUSCOPRIME -10 TABLETS) | Batch PT-102441Mfg Oct 2024 · Exp Sep 2026 | Assay of Hyoscine ButylbromideAssay | RDTL ChandigarhCDSCO lab | Jan 2025 |
| Natamycin Ophthalmic Suspension IP (Nataprime Eye Drops) | Batch PE062308Mfg Jun 2023 · Exp May 2025 | SterilitySterility | CDL KolkataCDSCO lab | Oct 2024 |
| Gentamicin Sulphate Injection IP (P- Genta Injection) | Batch PA022415Mfg Feb 2024 · Exp Jan 2026 | pHpH | CDTL MumbaiCDSCO lab | Sep 2024 |
| Cefoperazone Injection IP. (NOZACEF-1 GM) | Batch PD042309Mfg Apr 2023 · Exp Mar 2025 | Assay of CefoperazoneAssay | RDTL GuwahatiState lab | Dec 2023 |
| Inmecin R (Indomethacin Sustained Release Capsules U.S.P.) | Batch PC-111958Mfg Nov 2019 · Exp Apr 2022 | DissolutionDissolution | CDL KolkataCDSCO lab | May 2021 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.